PURPOSE: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). METHODS: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. RESULTS: AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p = 0.001). CONCLUSIONS: AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.
PURPOSE: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancerpatients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). METHODS: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. RESULTS:AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p = 0.001). CONCLUSIONS:AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancerpatients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.
Authors: Ilse A J van Rooij; Frank J M Broekmans; Gabrielle J Scheffer; Caspar W N Looman; J Dik F Habbema; Frank H de Jong; Bart J C M Fauser; Axel P N Themmen; Egbert R te Velde Journal: Fertil Steril Date: 2005-04 Impact factor: 7.329
Authors: André Hazout; Philippe Bouchard; David B Seifer; P Aussage; Anne Marie Junca; Paul Cohen-Bacrie Journal: Fertil Steril Date: 2004-11 Impact factor: 7.329
Authors: Kannamannadiar Jayaprakasan; Bruce Campbell; James Hopkisson; Ian Johnson; Nick Raine-Fenning Journal: Fertil Steril Date: 2008-11-30 Impact factor: 7.329
Authors: Ilse A J van Rooij; Evelyn de Jong; Frank J M Broekmans; Caspar W N Looman; J Dik F Habbema; Egbert R te Velde Journal: Fertil Steril Date: 2004-06 Impact factor: 7.329
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: M M Lee; P K Donahoe; T Hasegawa; B Silverman; G B Crist; S Best; Y Hasegawa; R A Noto; D Schoenfeld; D T MacLaughlin Journal: J Clin Endocrinol Metab Date: 1996-02 Impact factor: 5.958
Authors: Hannah K Weir; Michael J Thun; Benjamin F Hankey; Lynn A G Ries; Holly L Howe; Phyllis A Wingo; Ahmedin Jemal; Elizabeth Ward; Robert N Anderson; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2003-09-03 Impact factor: 13.506